PALLIATIVE
Both sorafenib and TACE are palliative treatments for advanced HCC.
This model permits the clinician to enter a patient’s clinical features and access directly, the predicted survival for either treatment. As such it may be considered as a Clinical Decision Aid.
Note that sorafenib is more competitive in those in whom vascular invasion is not present and/or are HCV positive*. HCV status refers to Anti-HCV. Remember to hit the ‘calculate’ button each time the patient’s input data changes.
*Jackson et al., Journal of Clinical Oncology 2017, 35:622-628; Bruix et al., Journal of Hepatology 2017, 67: 999–1008